Specialty Pharmacy

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

Unintentional weight loss may allow physicians to detect cancer sooner.

Burosumab (Crysvita, Ultragenyx) is the first treatment approved for x-linked hypophosphatemia in adults and children ages 1 and older.

Brandon Newman, PharmD, CSP, Program Director, Vanderbilt Specialty Pharmacy, speaks about how specialty pharmacies have to adjust their operations to meet the needs of their patients.

Following the approval of voretigene neparvovec, new treatments are on the horizon for retinitis pigmentosa.

When deciding to include a pharmacy in a distribution network, a manufacturer will look for factors that positively differentiate the pharmacy, as well as factors that will likely help the target patient population.

Top news of the week from Specialty Pharmacy Times.

Several barriers to value-based care exist, including finances and cost, meaning both the financial investments required by small- and mid-sized provider groups and the size of corresponding incentives.

Patients with severe hemophilia are at the highest risk for spontaneous bleeds, therefore are associated with the highest costs.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Spending on specialty medications is rapidly approaching half of overall medicine spending from a small volume of prescriptions filled.

Pharmacy benefit manager reports specialty drugs drive 97% of spending for hereditary angioedema care.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Thirty two million Americans are affected by migraines, and women are affected 3 times more than men.

Managed care organizations and pharmacy benefit managers are increasingly using strict approaches to manage drugs, including formulary exclusions.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Howard Cohen, RPh, MS, FASHP, from Smilow Cancer Hospital, Yale-New Haven Health, discusses how information technology can be utilized to improve medication adherence on patients with cancer.

Patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%.

Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.

A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.

Top news of the day from across the health care landscape.

Last year, 41% of pharmacy drug spending was for specialty drugs compared with 59% for traditional drugs.

The drive towards value-based care could accelerate through competition among health plans.

Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.

Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.

Top news of the day from across the health care landscape.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacists Director at Florida Cancer Specialists, discusses important considerations for managing oral chemotherapy care plans and improving adherence in patients.

With the growing use of digital patient identification to conduct business it comes as no surprise that many people have sought to take advantage of Medicare members.

New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.

Epidiolex would be the first plant-based cannabinoid approved by the FDA and would create a new category of anti-epileptic drugs.